WuXi Biologics Streamlines Biopharmaceutical Manufacturing
References: wuxibiologics & newswire
WuXi Biologics has achieved a significant milestone in biopharmaceutical manufacturing with its WuXiUP™ platform, which now enables fully automated, continuous drug substance production at pilot scale.
WuXi Biologics' system integrates advanced technologies such as membrane chromatography and real-time Process Analytical Technology to streamline production and maintain stringent quality control. By operating continuously with minimal manual intervention, the automated, continuous drug substance production platform enhances efficiency, reduces potential errors, and increases output. This is clearly demonstrated by its ability to sustain cell culture for 24 days with yields exceeding 110 g/L. WuXi Biologics' WuXiUP™ platform also boasts a downstream purification process that benefits from high-efficiency membrane chromatography, which accelerates mass transfer and improves productivity by five to ten times compared to conventional methods.
The technology’s proven success — with one molecule already receiving BLA approval and 11 others in IND stages — further reinforces WuXi Biologics' credibility.
Image Credit: WuXi Biologics
WuXi Biologics' system integrates advanced technologies such as membrane chromatography and real-time Process Analytical Technology to streamline production and maintain stringent quality control. By operating continuously with minimal manual intervention, the automated, continuous drug substance production platform enhances efficiency, reduces potential errors, and increases output. This is clearly demonstrated by its ability to sustain cell culture for 24 days with yields exceeding 110 g/L. WuXi Biologics' WuXiUP™ platform also boasts a downstream purification process that benefits from high-efficiency membrane chromatography, which accelerates mass transfer and improves productivity by five to ten times compared to conventional methods.
The technology’s proven success — with one molecule already receiving BLA approval and 11 others in IND stages — further reinforces WuXi Biologics' credibility.
Image Credit: WuXi Biologics
Trend Themes
-
Automated Biomanufacturing — The advent of fully automated drug substance production highlights opportunities for increased efficiency and higher yields in the biomanufacturing industry.
-
Continuous Production Processes — Implementing continuous manufacturing in biopharmaceuticals presents a shift from batch processing, improving production capacity and reducing time-to-market for new drugs.
-
Advanced Membrane Chromatography — The use of high-efficiency membrane chromatography allows for greater mass transfer rates, significantly enhancing purification processes and productivity.
Industry Implications
-
Biopharmaceutical Manufacturing — The innovative WuXiUP™ platform demonstrates new possibilities for streamlining drug production with automation and advanced technologies, setting new standards in the industry.
-
Process Analytical Technology — Integrating real-time analytical tools in manufacturing processes offers the potential for improved quality control and operational efficiency across pharmaceutical production.
-
Pharmaceutical Automation Solutions — Automation in drug manufacturing paves the way for reduced manual intervention, potentially lowering error rates and operational costs within the pharmaceutical sector.
4.3
Score
Popularity
Activity
Freshness
